November 10, 2021 -Johnson & Johnson Innovation, together with California Life Sciences (CLS), AbbVie and 5AM Ventures, announced today that Glyphic Biotechnologies, Nutrible, and MabSwitch, Inc have been selected as the awardees inCLSA Inspire QuickFire Challenge for Diverse Innovators。
To help advance their research, the three awardees will receive $50,000 each in grant funding from California Life Sciences’ (CLS) Racial and Social Equity Initiative.
- Glyphic Biotechnologies
Glyphic Biotechnologies是一家生物技术创业公司，正在开发单分子，下一代蛋白测序平台，并在开发各种背景患者的个性化精密癌症疫苗中应用。 - Nutrible
Nutribleis a virtual registered dietitian platform that serves a one-stop-shop in the fight against food deserts by providing nutrition education and delivering healthy food directly to patients who need it most. - MabSwitch, Inc
MabSwitch, Inc is a biotechnology company that aims to develop regulatable next generation immunotherapies based on a proprietary universal allosteric switch module for antibodies (UNASMA) technology platform to address diseases of significant unmet medical need.
此外，草甘膦将成为2022年春季Quickfire挑战赛公司的第一家，从经验丰富的行业退伍军人组获得12个小时的咨询服务，以推动其商业化策略
The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.
About Johnson & Johnson Innovation
ld乐动Johnson＆Johnson Innovation LLC在制药，医疗设备和消费者健康领域工作，通过催化最佳想法（无论它们在世界范围的地方）加速早期的转型解决方案。我们通过利用深厚的科学能力以及广泛的工具，包括定制的交易结构，公司创建，孵化和启动服务，资本投资和其他创新的商业模式来实现这一目标，以满足企业家，科学家和新兴的各种需求公司。我们的目标是通过与全球生态系统的合作和合作伙伴关系来帮助生活科学和卫生技术创新蓬勃发展，以便我们可以共同改变人类健康的轨迹。结识我们热情的科学技术专家团队，并学习如何与我们合作www.jnjinnovation.com。
关于加利福尼亚生命科学（CLS）
California Life Sciences (CLS) is the state’s most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. With offices in South San Francisco, San Diego, Sacramento, Los Angeles, and Washington DC, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world. Visit CLS atwww.califesciences.org, and follow us on Twitter@CALifeSciences,Facebook,LinkedIn和YouTube。
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com。关注@abbvieTwitter,Facebook,Instagram,YouTube和LinkedIn
大约凌晨5点
成立于2002年，凌晨5点积极投资于下一代生物技术公司。自成立以来，大约筹集了约15亿美元，凌晨5点投资了73家公司，包括Arvinas（NASDAQ：ARVN），Audentes Therapeutics（NASDAQ：BOLD），Crinetics Pharmaceuticals（NASDAQ：CRNX），DVS Sciences（由Fluidigmm），EumiDigmmicics（Eunviredsics），Eunviredics（Eunviredsics）takeda），Flexion Therapeutics（NASDAQ：FLXN），同源药物（NASDAQ：FIXX），IKARIA（由Mallinckrodt获得），ILYPSA（由Amgen）（由Amgen），Marcadia Biotech收购Pearl Therapeutics（由Astrazeneca收购）和Relypsa（由Vifor Pharma收购）。有关更多信息，请访问www.5amventures.com。
